The following individuals have identified relevant financial relationships with ineligible companies to disclose: Manal F Abdelmalek, MD, MPH (Speaker) Advisory Board or Panel 89Bio , Akero , Boehringer Ingelheim , CLDF , Hanmi , Intercept , Inventiva , Novo Nordisk Consultant Regeneron Grants / Research Support 89Bio , Akero , CLDF , Hanmi , Inventiva , Regeneron Speakers Bureau or other Promotional Education Fishawack Inc LLC Stock / Shareholder (self- managed) Intercept The relationships reported above are related to the following therapeutic area: Gastroenterology Sonal Kumar, MD, MPH (Speaker) Advisory Board or Panel Gilead Sciences , Intercept Pharmaceuticals , Ipsen , Madrigal , Novo Nordisk Consultant GlaxoSmithKline , Intercept Pharmaceuticals Grants / Research Support Gilead Sciences , Intercept Pharmaceuticals , Ipsen , Madrigal , Novo Nordisk Speakers Bureau or other Promotional Education Gilead Sciences , Intercept Pharmaceuticals , Ipsen , Madrigal , Novo Nordisk The relationships reported above are related to the following therapeutic area: Gastroenterology Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner) Speakers Bureau or other Promotional Education AstraZeneca , Bristol-Myers Squibb , DSI , Exilixis , Gilead Sciences , Pfizer , Stemline The relationships reported above are related to the following therapeutic area: Oncology The following individuals have no relevant financial relationships with ineligible companies to disclose: Joseph J Saseen, PharmD, BCPS, BCACP, CLS (Moderator) Jason Welch, MD (Reviewer) Stephanie Joyce, PA, MSPAS, MS, RD (Planner) All PRIME staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose

Some prior work on GLP-1 drugs and mental health did not show such strong signals, which means current findings should be treated as promising rather than conclusive
Diverse Drug-Resistance Mechanisms can Emerge From Drug-Tolerant Cancer Persister Cells
PloS One 10, e0121933
Cancers 14 , 5110 (2022)